A. Goorin

发表

Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations.

S. Friend, M. Link, M. Gebhardt, 1994, Medical and pediatric oncology.

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

J. Shuster, M. Link, C. Pratt, 1986, The New England journal of medicine.

H. Abelson, A. Goorin, E. Frei, 1985, The New England journal of medicine.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Paul A Meyers, Mark D Krailo, E. Kleinerman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of left ventricular contractility in patients receiving doxorubicin.

S. Colan, S. Papish, I. Henderson, 1983, Annals of Internal Medicine.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

G. Demetri, A. Huvos, R. Maki, 2003, Cancer.

Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children

S. Sallan, I. Henderson, K. Borow, 1981, Cancer.

Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

S. Lipshultz, A. Perez-Atayde, A. Goorin, 1990, The Journal of pediatrics.

Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III.

N. Jaffe, M. Link, M. Gebhardt, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer in relatives of survivors of childhood sarcoma

F. Li, A. Janov, A. Goorin, 1991, Cancer.

Monitoring for anthracycline cardiotoxicity.

S. Colan, J. Krischer, S. Sallan, 1994, Pediatrics.

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

M. Link, H. Abelson, G. P. Beardsley, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors.

S. Lipsitz, A. Goorin, V. Kharasch, 1996, Medical and pediatric oncology.

Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.

M. Link, M. Devidas, M. Gebhardt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study.

A. Cantor, M. Link, A. Goorin, 1995, Medical and pediatric oncology.

Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study.

J. Shuster, M. Link, W. Meyer, 1991, Clinical orthopaedics and related research.

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

K. S. Hall, L. Trani, M. Sydes, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation.

Shaun Parsons, E. Guinan, K. Deans, 1996, Blood.

Noninvasive detection of left ventricular dysfunction in children using afterload challenge

K. Borow, A. Goorin, Robertag . Williams, 1982 .

Chromosome 13 homozygosity in osteosarcoma without retinoblastoma.

T. Dryja, W. Cavenee, A. Goorin, 1986, American journal of human genetics.

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease.

N. Tarbell, C. Chan, A. Goorin, 1996, The Journal of infectious diseases.

Hepatic and skeletal muscle transport of cycloleucine during starvation.

A. Goorin, S. Adibi, S. Nallathambi, 1972, The American journal of physiology.

Progress against childhood cancer: the Pediatric Oncology Group experience.

J. Krischer, L. Frankel, J. Shuster, 1992, Pediatrics.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1990. A 15-year-old girl with multiple radiolucent bony defects and multiple pulmonary nodules.

A. Rosenberg, A. Goorin, 1990, The New England journal of medicine.

Ovarian toxicity after chemotherapy: Possible association with ifosfamide administration

M. Palmert, A. Goorin, S. W. Alexander, 2004, Pediatric blood & cancer.

Current Treatment of Osteosarcoma

A. Goorin, W. Ferguson, 2001, Cancer investigation.

Experience with multiagent chemotherapy for osteosarcoma. Improved outcome.

A. Goorin, J. Andersen, 1991, Clinical orthopaedics and related research.

Ototoxicity in children treated for osteosarcoma

B. Fligor, A. Goorin, H. Grier, 2009, Pediatric blood & cancer.

Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

P. Leavey, J. Healey, M. Devidas, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

K. S. Hall, M. Sydes, P. Leavey, 2016, The Lancet. Oncology.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

E. Kleinerman, A. Huvos, J. Healey, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study.

J. Shuster, M. Link, W. Meyer, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

M. Link, M. Devidas, M. Gebhardt, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group

E. Kleinerman, D. Hawkins, M. Bernstein, 2010, Clinical Cancer Research.

Phase I I/III T rial o f E toposide a nd H igh-Dose I fosfamide in N ewly D iagnosed M etastatic O steosarcoma: A P ediatric Oncology G roup T rial

M. Link, M. Devidas, M. Gebhardt, 2002 .

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

J. Krischer, S. Lipshultz, D. Cuthbertson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

E J Orav, S R Lipsitz, S. Lipsitz, 1995, The New England journal of medicine.

Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.

M. Link, A. Goorin, P. Gieser, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients.

R. Gelber, N. Jaffe, M. Link, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide/Carboplatin/Etoposide (ICE) for Recurrent Malignant Solid Tumors of Childhood: A Pediatric Oncology Group Phase I/II Study

J. Krischer, F. Kung, C. Pratt, 1995, Journal of pediatric hematology/oncology.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

M. Sydes, J. Gerss, R. Randall, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

M. Link, M. Devidas, L. Helman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy in the Treatment of Osteosarcoma: Results of the Multi-Institutional Osteosarcoma Study

J. Shuster, M. Link, W. Meyer, 1988 .

Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

Zhengjia Chen, M. Bernstein, L. Teot, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of trimethoprim‐sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia

R. Gelber, S. Sallan, M. Levin, 1985, Pediatric infectious disease.

Presurgical Window of Carboplatin and Surgery and Multidrug Chemotherapy for the Treatment of Newly Diagnosed Metastatic or Unresectable Osteosarcoma: Pediatric Oncology Group Trial

M. Link, M. Devidas, M. Gebhardt, 2001, Journal of pediatric hematology/oncology.

Osteosarcoma in young children

G. Vawter, M. Gebhardt, A. Perez-Atayde, 1991, Cancer.

Methotrexate osteopathy in patients with osteosarcoma.

T. Laor, A. Goorin, D. Jaramillo, 1997, Radiology.

Analysis of serum insulin growth factor‐1 concentrations in localized osteosarcoma: A children's oncology group study

J. Toretsky, M. Bernstein, A. Goorin, 2014, Pediatric blood & cancer.

Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.

M. Link, A. Goorin, D. Strother, 1995, Medical and pediatric oncology.

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

S. Lipshultz, M. Devidas, M. Bernstein, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience

J. Krischer, S. Lipshultz, D. Cuthbertson, 1997 .

High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results.

K. Fellows, N. Jaffe, G. Vawter, 1981, Cancer treatment reports.

P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial

M. Devidas, M. Bernstein, A. Goorin, 2004 .

P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial.

M. Devidas, M. Bernstein, A. Goorin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in osteosarcoma survivors.

M. Gebhardt, A. Goorin, D. Harmon, 1994, Oncology.

Adjuvant chemotherapy for osteogenic sarcoma.

A. Goorin, 1988, European journal of cancer & clinical oncology.

Long-Term Results of Limb Salvage and Amputation in Extremity Osteosarcoma DFCI/TCH Results in Patients Receiving Postoperative Weekly High-Dose Methotrexate and Doxorubicin

H. Watts, M. Gebhardt, A. Perez-Atayde, 1989 .

Long-Term Results of Limb Salvage and Amputation in Extremity Osteosarcoma

N. Jaffe, H. Watts, M. Gebhardt, 1989 .

Hearing loss in children with osteosarcoma

B. Fligor, A. Goorin, H. Grier, 2007 .

Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

S. Lipshultz, J. Healey, M. Devidas, 2016, Pediatric blood & cancer.

Adjuvant chemotherapy for osteosarcoma: a decade of experience.

H. Abelson, A. Goorin, E. Frei, 1981, The Surgical clinics of North America.

K. S. Hall, M. Sydes, P. Leavey, 2016, The Lancet. Oncology.

Monitoring for anthracycline cardiotoxicity.: 10

S. Colan, J. Krischer, S. Sallan, 1994 .

In reply [10]

M. Bernstein, L. Teot, A. Goorin, 2007 .